HLA-Haploidentical Anti-CD7 Chimeric Antigen Receptor (CAR) T Cells for Transplant-Naïve Patients With Refractory T-Cell Acute Lymphoblastic Leukemia.
CAR-T therapy designed for T-cell leukemia expands eligibility to transplant-naïve patients, potentially reaching more children with this aggressive cancer.
This letter reports the use of HLA-haploidentical anti-CD7 CAR T cells in transplant-naïve patients with refractory T-cell ALL at Bambino Gesù Children's Hospital, a leading CAR-T center, potentially expanding CAR-T eligibility to a broader population without prior transplantation. The approach is highly novel given that anti-CD7 CAR-T for T-ALL is itself experimental, and the transplant-naïve context removes a major eligibility barrier for this aggressive hematologic malignancy.
What the study was
- Study design
- Clinical case report/Letter
- Population
- Transplant-naïve patients with refractory T-cell ALL at Bambino Gesù Children's Hospital Rome (IRCCS)
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- American Journal of Hematology
Why it surfaced
Novel anti-CD7 CAR-T approach in transplant-naïve T-ALL from a leading pediatric CAR-T center; Letter format typically excluded but included under sparse-topic exception for T-ALL CAR-T which has limited daily literature.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.